The enigma of pulmonary hypertension after splenectomy - Does the megakaryocyte provide a clue?

QJM: An International Journal of Medicine

Volumn 102, Issue 10, 2009, Pages 743-745

  Thachil, J ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN;

ARTICLE; CELL SIZE; DISEASE ACTIVITY; DOPPLER ECHOGRAPHY; DRUG ACTIVITY; EXTRAMEDULLARY HEMATOPOIESIS; GAUCHER DISEASE; HEREDITARY HEMOLYTIC ANEMIA; HUMAN; LUNG CIRCULATION; MEGAKARYOCYTE; MYELOID LEUKEMIA; PATHOGENESIS; PERIPHERAL VASCULAR SYSTEM; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SPLENECTOMY; SYSTEMIC CIRCULATION;

HEMATOLOGIC DISEASES; HUMANS; HYPERTENSION, PULMONARY; LUNG; MEGAKARYOCYTES; SPLENECTOMY;

EID: 70349658458     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcp092     Document Type: Article

References (26)

1. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004; 351:1655-65.
2. Gladwin M, Sachdev V, Jison M, Shizukuda Y, Plehn JF, Minter K, et al Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004; 350:886-95.
3. Du ZD, Roguin N, Milgram E, Saab K, Koren A. Pulmonary hypertension in patients with thalassemia major. Am Heart J 1997; 134:532-7.
4. Dingli D, Utz JP, Krowka MJ, Oberg AL, Tefferi A. Unexplained pulmonary hypertension in chronic myeloproliferative disorders. Chest 2001; 120:801-8.
5. Hoeper MM, Nidermeyer J, Hoffmeyer F, Flemming P, Fabel H. Pulmonary hypertension after splenectomy? Ann Intern Med 1999; 130 506-9.
6. Phrommintikul A, Sukonthasarn A, Kanjanavanit R, Nawarawong W. Splenectomy: A strong risk factor for pulmonary hypertension in patients with thalassaemia. Heart 2006; 92:1467-72.
7. Peacock AJ. Pulmonary hypertension after splenectomy: A consequence of loss of the splenic filters or is there something more? Thorax 2005; 60:983-4.
8. Jaïs X, Ioos V, Jardim C, Sitbon O, Parent F, Hamid A, et al. Splenectomy and chronic thromboembolic pulmonary hypertension. Thorax 2005; 60:1031-4.
9. Zucker-Franklin D, Philipp CS. Platelet production in the pulmonary capillary bed: New ultrastructural evidence for an old concept. Am J Pathol 2000; 157:69-74.
10. Hill G, McClean D, Fraser R, Hart D, Crozier I, Snowden J, et al. Pulmonary hypertension as a consequence of alveolar capillary plugging by malignant megakaryocytes in essential thrombocythaemia. Aust N Z J Med 1996; 26:852-3.
11. Mistry PK, Sirrs S, Chan A, Pritzker MR, Duffy TP, Grace ME, et al Pulmonary hypertension in type 1 Gaucher's disease: Genetic and epigenetic determinants of phenotype and response to therapy. Mol Genet Metab 2002; 77:91-8.
12. Theise ND, Ursell PC. Pulmonary hypertension and Gaucher's disease: logical association or mere coincidence? Am J Pediatr Hemat Oncol 1990; 12:74-6.
13. Tefferi A. Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol 2005; 23:8520-30.
14. Dickinson CJ, Martin JF. MK and platelet clumps as the cause of finger clubbing. Lancet 1987; 2:1434-5.
15. Atkinson S, Fox SB. Vascular endothelial growth factor (VEGF)-A and platelet derived growth factor (PDGF) play a central role in the pathogenesis of digital clubbing. J Pathol 2004; 203:721-8.
16. Kawakami T, Kimura S, Kato M, Mizoguchi M, Soma Y. Transforming growth factor-beta overexpression in cutaneous extramedullary hematopoiesis of a patient with myelodysplastic syndrome associated with myelofibrosis. J Am Acad Dermatol 2008; 58:703-6.
17. Battinelli E, Loscalzo J. Nitric oxide induces apoptosis in megakaryocytic cell lines. Blood 2000; 95:3451-9.
18. Boutet K, Montani D, Jaïs X, Yaïci A, Sitbon O, Simonneau G, et al. Therapeutic advances in pulmonary arterial hypertension. Ther Adv Respir Dis 2008; 2:249-65.
19. Pozner RG, Negrotto S, D'Atri LP, Kotler ML, Lazzari MA, Gomez RM, et al. Prostacyclin prevents nitric oxide-induced megakaryocyte apoptosis. Br J Pharmacol 2005; 145:283-92.
20. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005; 353 1412-3.
21. Perros F, Montani D, Dorfmüller P, Durand-Gasselin I, Tcherakian C, Le Pavec J, et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2008; 178:81-8.
22. Hirose Y, Kiyoi H, Iwai M, Yokozawa T, Ito M, Naoe T. Successful treatment with imatinib mesylate of a CML patient in megakaryoblastic crisis with severe fibrosis. Int J Hematol 2002; 76:349-53.
23. Anstee QM, Wright M, Goldin R, Thursz MR. Parenchymal extinction: coagulation and hepatic fibrogenesis. Clin Liver Dis 2009; 13 117-26.
24. Vittet D, Chevillard C. Thrombin interactions with cells of the megakaryocytic lineage. Blood Coagul Fibrinolysis 1993; 4 759-68.
25. Krauth MT, Lechner K, Neugebauer EA, Pabinger I. The post-operative splenic/portal vein thrombosis after splenectomy and its prevention - an unresolved issue. Haematologica 2008; 93:1227-32.
26. Landolfi R, Di Gennaro L, Falanga A. Thrombosis in myeloproliferative disorders: Pathogenetic facts and speculation. Leukemia 2008; 22:2020-8.